NOXXON Pharma N.V. Amsterdam, The Netherlands

Half-Year Financial Report 2021

30 June 2021

NOXXON Pharma N.V. Half-Year Financial Report 2021

Contents

Condensed consolidated interim financial statements

as of 30 June 2021

3

Management and Activity Report

19

Business Highlights

19

Financial Highlights

24

Transactions between Related Parties

29

Risk Factors

30

Declaration by the Person Responsible for

2021 Half-Year Financial Report

31

1

NOXXON Pharma N.V. Half-Year Financial Report 2021

Forward-looking statements

This Half-Year Financial Report contains statements that constitute forward-looking statements. Forward-looking statements appear in a number of places in this Half-Year Financial Report and include, but are not limited to, statements regarding our intent, belief or current expectations. Forward-looking statements are based on management estimates and on management's beliefs and assumptions and on information currently available to the management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those identified under the section "Risk Factors" in this Half-Year Financial Report.

Such estimates have been made in good faith and represent the current beliefs of management. Management believes that such estimates are founded on reasonable grounds. However, by their nature, estimates may not be correct or complete. These statements reflect the Company's current knowledge and its expectations and projections about future events. Many of these forward-looking statements contained in this Half-Year Financial Report can be identified by the context of such statements or words such as "anticipate," "believe", "estimate", "expect", "intend", "plan", "project", "target", "may", "will", "would", "could", "might" or "should" or "potential" or similar terminology. By their nature, forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Group's control that could cause the Group's actual results and performance to differ materially from any expected future results or performance expressed or implied by any forward-looking statements. Forward-looking statements speak only as of the date they are made and the Group does not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events.

2

NOXXON Pharma N.V. Half-Year Financial Report 2021

Condensed consolidated interim financial statements as of 30 June 2021

Condensed consolidated interim statements of financial position as of 30 June 2021

Condensed consolidated interim statements of comprehensive loss for the six-month period ended 30 June 2021

Condensed consolidated interim cash-flow statements for the six-month period ended 30 June 2021

Condensed consolidated interim statements of changes in shareholder's equity for the six-month period ended 30 June 2021

Notes to the condensed consolidated interim financial statements as of 30 June 2021

3

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Noxxon Pharma NV published this content on 22 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 October 2021 17:53:03 UTC.